FDA Approves Abuse-Deterrent 10 mg Oxycodone Hydrochloride for Severe Pain
Drug Topics
OCTOBER 29, 2024
The addition of a 10 mg oxycodone hydrochloride tablet improves dosing flexibility and precision.
Tue.Oct 29, 2024
404 
STAT+: Dreams of cancer vaccines are becoming more real. Here are 9 scientists making it happen
STAT
OCTOBER 29, 2024
Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Shadowed by the successes of other therapies, the field of cancer vaccines was “seemingly dying,” Sullivan said.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Guselkumab’s Promising Results as First Subcutaneous IL-23 Inhibitor to Treat Chron’s
Drug Topics
OCTOBER 29, 2024
Johnson & Johnson announced results from its phase 3 GRAVITI trial exploring guselkumab’s results in subcutaneous (SC) induction and maintenance therapy for treating Chron’s disease.
STAT+: VCs move to launch U.S.-based companies to develop drugs developed in China
STAT
OCTOBER 29, 2024
As Chinese biopharma companies rise on the international stage, they are increasingly finding VC partners — in the United States. U.S. companies have long signed licensing deals with Chinese drugmakers. But increasingly American venture capitalists are building U.S.-based companies from scratch to test and ultimately seek to commercialize innovative drugs developed in China.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Best Practices for Proactively Preventing PBM Audit Issues | NCPA 2024
Drug Topics
OCTOBER 29, 2024
Trent Thiede, PharmD, MBA, president of PAAS National, discusses best practices that pharmacy teams can implement to proactively prevent audit issues before they arise.
STAT+: Warren wants close FTC scrutiny of drug distributors buying cancer medical groups
STAT
OCTOBER 29, 2024
Sen. Elizabeth Warren (D-Mass.) is urging the Federal Trade Commission to scrutinize recent deals from McKesson and Cardinal Health to buy oncology practices, saying those transactions pose “clear, anticompetitive risks.” McKesson, Cardinal Health, and Cencora are the three dominant wholesalers that distribute drugs and medical products.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Opinion: I’m the director of the Center for Medicare. Here’s how we executed the first round of drug price negotiation
STAT
OCTOBER 29, 2024
The historic Inflation Reduction Act of 2022 has fundamentally improved the affordability of and access to prescription drugs for millions of people with Medicare. The law laid out aggressive timelines for implementing the Medicare Drug Price Negotiation Program. As the director of Medicare, my team and I worked thoughtfully and diligently to stand up the program — on time and successfully.
How Participating in Pharma-Sponsored Programs Can Benefit Your Pharmacy
Drug Topics
OCTOBER 29, 2024
A.J. Lipka, Business Development Lead of Network Growth at Outcomes, discussed the impact of pharmacy-sponsored programming.
Novartis pays $150m upfront for Monte Rosa degrader drug
pharmaphorum
OCTOBER 29, 2024
The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership – which has seen a $150 million upfront payment from Novartis alongside a pledge for up to $2.1 billion in milestones – gives the Swiss pharma group rights to Monte Rosa's VAV1-directed molecular glue degrader programme.
Importance of NCPA’s Annual Conference to the Independent Pharmacy Community | NCPA 2024
Drug Topics
OCTOBER 29, 2024
At the NCPA 2024 Annual Convention and Expo, Drug Topics asked different pharmacists what they think the importance of the conference is to the independent pharmacy community.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Bristol Myers partner Zai Lab plots KarXT filing in China after trial win
Fierce Pharma
OCTOBER 29, 2024
After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers Squibb and its partners are moving fast to expand the global reach of th | In a phase 3 bridging study run by Zai Lab in China, Bristol Myers Squibb's KarXT helped schizophrenia patients chart a 9.2-point total-score reduction on the Positive and Negative Syndrome Scale versus placebo at week 5, teeing up a forthcoming regulatory filing.
STRIPE Names Recipients of the Inaugural Double Helix Awards
Pharmacy Times
OCTOBER 29, 2024
The STRIPE Double Helix Awards celebrate individuals and organizations that have made exceptional contributions to the field of pharmacogenomics.
Chiesi announces phase 3 results from enzyme-replacement study
Pharmafile
OCTOBER 29, 2024
Chiesi Global Rare Diseases have announced the results from their BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug ELFABRIO at twice the approved dose in patients who have been treated with agalsidase alfa or beta. The current approved dose of pegunigalside alfa-iwxj (ELFABRIO) is 1miligramg (mg) per kilogram (kg) administered every two weeks. […] The post Chiesi announces phase 3 results from enzyme-replacement study appeared first on Pharmafile.
How AZ’s respiratory wins are ramping up for a bigger prize in COPD
PharmaVoice
OCTOBER 29, 2024
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Researchers Begin Phase 3 Trial Assessing Adjuvant V940 With Pembrolizumab to Treat Non–Small Cell Lung Cancer
Pharmacy Times
OCTOBER 29, 2024
The INTerpath-009 trial assessed a combination of V940 with pembrolizumab among individuals with stage II, IIIA, IIIB (N2) non–small cell lung cancer.
Walgreens lays off 250 support center employees as part of cost-saving strategy
Fierce Healthcare
OCTOBER 29, 2024
Walgreens is conducting another round of layoffs as the drugstore giant looks to significantly cut costs and improve its financial performance. It's the third round of cuts in 2024. | Walgreens is conducting another round of layoffs as the drugstore giant looks to significantly cut costs and turnaround its financial performance.
American Pharmacists Month: Stephanie Y. Crawford, PhD, MPH, on Mentorship, Health Equity, and the Expanding Role of Pharmacists
Pharmacy Times
OCTOBER 29, 2024
Stephanie Y. Crawford, PhD, MPH, highlights the expanded roles of pharmacists in clinical and non-clinical settings and their increased role in patient care, sharing personal experiences where pharmacists have been instrumental in supporting her family's health needs.
MSSP ACOs saves Medicare $2.1 billion in 2023, the largest savings in program history
Fierce Healthcare
OCTOBER 29, 2024
Accountable care organizations saved Medicare $2.1 billion, the largest yearly savings in program history, in 2023, the Centers for Medicare & Medicaid Services revealed on Tuesday. | Accountable care organizations (ACOs) saved Medicare $2.1 billion, the largest yearly savings in program history, in 2023, the Centers for Medicare & Medicaid Services (CMS) revealed Oct. 29.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Opinion: Fecal transplants are saving lives — but are now at risk
STAT
OCTOBER 29, 2024
Twenty years ago, a respected colleague asked me to perform a “poop transplant” on a local schoolteacher with multiply recurrent C. difficile infection. I was incredulous and skeptical, but my colleague (a friend but a forceful one) persisted until I ultimately acquiesced. Soon I was in a hazmat suit blenderizing stool and performing my first (subsequently named) fecal microbiota transplant, or FMT.
Oracle Health will offer next-gen EHR in 2025 embedded with AI and analytics tools
Fierce Healthcare
OCTOBER 29, 2024
Oracle Health plans to release a new electronic health record platform in 2025, the company announced Tuesday. | Oracle Health executive Seema Verma stressed that the next-gen EHR platform is not a "refurbished Cerner EHR." "You can’t bolt new innovation onto something built in the 1990s," she said.
D.C. Diagnosis: Could RFK Jr. go ‘wild’ on health and medicine?
STAT
OCTOBER 29, 2024
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Hello and happy Tuesday, D.C. Diagnosis readers! We are one week from Election Day; I probably don’t need to remind you.
FDA Grants Accelerated Approval to Asciminib for Adult Patients With Newly Diagnosed Ph+ CML-CP
Pharmacy Times
OCTOBER 29, 2024
The accelerated approval comes after 48-week major molecular response rate data.
Athenahealth debuts ambient scribe choose-your-player product with Suki, iScribe
Fierce Healthcare
OCTOBER 29, 2024
Athenahealth will release a product that allows clinicians in the same practice to choose which AI ambient scribe they want to use and easily use it in their workflow. | Athenahealth partnered with Suki AI and iScribe to let clinicians choose their preferred scribe without locking them into a long-term contract.
STAT+: Eli Lilly says modified dosing of its Alzheimer’s drug may be safer
STAT
OCTOBER 29, 2024
A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show. But it’s unclear whether the new dosing schedule, if approved by regulators, will convince doctors that the treatment is safer for patients. At 24 weeks of a Phase 3b trial, 24% of those taking the standard regimen experienced a side effect called ARIA-E, a kind of brain swelling.
NHS funding boost confirmed ahead of tomorrow's Budget
pharmaphorum
OCTOBER 29, 2024
UK government confirms £1.8bn funding boost to NHS to cut waiting lists, including £1.
FDA Grants Approval to Oxycodone Hydrochloride Immediate-Release Tablets For Management of Severe Pain
Pharmacy Times
OCTOBER 29, 2024
The approval marks the first and only abuse-deterrent immediate release oxycodone formulation.
2024 PharmaVoice 100s: Rare Disease Warriors
PharmaVoice
OCTOBER 29, 2024
Pharma pros driving drug development and access for patients with high unmet needs.
Epinephrine Auto-Injectors May Not Be Reliably Effective in Preventing Fatal Anaphylaxis
Pharmacy Times
OCTOBER 29, 2024
Though auto-injectors are still considered an appropriate first-line treatment for anaphylaxis, limited evidence exists surrounding their effectiveness in preventing fatal anaphylaxis.
PHTI review of digital hypertension tools gives mixed results
pharmaphorum
OCTOBER 29, 2024
An evaluation of digital health technologies for hypertension by the Peterson Health Technology Institute (PHTI) finds some provide a clinical benefit, while others are lacking.On the plus side, the health technology assessment (HTA) body has concluded that tools to help people manage their antihypertensive drug treatment can deliver benefits in reduced blood pressure.
Pfizer bumps up revenue outlook by $1.5B in Paxlovid rebound amid criticism from activist investor Starboard
Fierce Pharma
OCTOBER 29, 2024
Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | The company is projecting yearly sales of $61 billion to $64 billion in a $1.5 billion boost from previous forecasts.
Pfizer rebuffs Starboard criticism as it raises forecasts
pharmaphorum
OCTOBER 29, 2024
Pfizer CEO Albert Bourla hit back at activist investor Starboard Value, saying measures to reset the pharma group are already well in hand
EC approves AstraZeneca’s Fasenra for EGPA treatment
Pharmaceutical Technology
OCTOBER 29, 2024
The EC has approved AstraZeneca's Fasenra as an add-on therapy for adults with relapsing or refractory EGPA.
AbbVie gets bigger in Alzheimer's R&D with Aliada takeover
pharmaphorum
OCTOBER 29, 2024
AbbVie agrees a $1.4bn cash deal to acquire Aliada Therapeutics, adding another anti-amyloid antibody to its Alzheimer's pipeline.
Let's personalize your content